Literature DB >> 18199244

Long-term outcome of patients with bipolar disorder commenced on lithium prophylaxis during hospitalization: a complete 15-year register-based follow-up.

Rasmus W Licht1, Per Vestergaard, Arne Brodersen.   

Abstract

OBJECTIVES: From placebo-controlled studies of up to two years duration, it has been established that lithium has preventive efficacy in bipolar disorder (BD). However, the effectiveness of lithium under routine conditions seems less pronounced. In the present study, the overall 15.3-year outcome in BD patients commenced on lithium is described.
METHODS: Ninety-one patients with BD consecutively commenced on prophylactic lithium treatment during hospitalization at the Aarhus University Psychiatric Hospital from 1981 to 1983 were followed until death or censoring occurred during up to 15.3 years of observation. Register-based outcome measures, available for all patients, included accumulated duration of admission and number of admissions. In addition, serious attempts were made to collect detailed information on treatment during follow up. Simple descriptive statistics were applied; potential independent associations between baseline variables and outcome were examined using logistic regression models.
RESULTS: Of the 91 patients, 27 patients died (six from suicide) during the observation period, which was an excess mortality compared to the general population. Fifty percent of the patients were admitted for more than one month per 20 months of observation and admitted more than once for each four years of observation. Only 19 (21%) patients were not admitted to hospital during the observation period. No statistically significant predictors of poor outcome could be identified. In addition to lithium prophylaxis given for variable lengths of time, the majority of the 36 (40%) patients, from whom treatment data were available, received various other drug treatments during follow-up.
CONCLUSIONS: The overall outcome in patients beginning prophylactic treatment is unsatisfactory. However, due to the observational design and the lack of detailed treatment information during the long follow-up period, inferences about the efficacy of lithium cannot be made from this study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18199244     DOI: 10.1111/j.1399-5618.2008.00499.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  6 in total

1.  Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication.

Authors:  Jules Angst; Lihong Cui; Joel Swendsen; Stéphane Rothen; Anibal Cravchik; Ronald C Kessler; Kathleen R Merikangas
Journal:  Am J Psychiatry       Date:  2010-08-16       Impact factor: 18.112

2.  Stability of lithium treatment in bipolar disorder - long-term follow-up of 346 patients.

Authors:  Anne Berghöfer; Martin Alda; Mazda Adli; Christopher Baethge; Michael Bauer; Tom Bschor; Paul Grof; Bruno Müller-Oerlinghausen; Janusz K Rybakowski; Alexandra Suwalska; Andrea Pfennig
Journal:  Int J Bipolar Disord       Date:  2013-07-31

Review 3.  Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics.

Authors:  M Alda
Journal:  Mol Psychiatry       Date:  2015-02-17       Impact factor: 15.992

4.  Comprehensive comparison of monotherapies for psychiatric hospitalization risk in bipolar disorders.

Authors:  Anastasiya Nestsiarovich; Aurélien J Mazurie; Nathaniel G Hurwitz; Berit Kerner; Stuart J Nelson; Annette S Crisanti; Mauricio Tohen; Ronald L Krall; Douglas J Perkins; Christophe G Lambert
Journal:  Bipolar Disord       Date:  2018-06-19       Impact factor: 6.744

Review 5.  Effects of somatic treatments on suicidal ideation and completed suicides.

Authors:  Elise M Hawkins; William Coryell; Stephen Leung; Sagar V Parikh; Cody Weston; Paul Nestadt; John I Nurnberger; Adam Kaplin; Anupama Kumar; Ali A Farooqui; Rif S El-Mallakh
Journal:  Brain Behav       Date:  2021-10-17       Impact factor: 2.708

6.  Prevalence of subthreshold hypomania and impact on internal validity of RCTs for major depressive disorder: results from a national epidemiological sample.

Authors:  Nicolas Hoertel; Yann Le Strat; Frédéric Limosin; Caroline Dubertret; Philip Gorwood
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.